A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic Antidepressant in Adults with Major Depressive Disorder
ID Number 15-1210Principal Investigator(s)
Department(s) or Division(s)
Mood and Anxiety Disorders Program - MAP
The purpose of this study is to evaluate the efficacy of sirukumab as an adjunctive treatment to antidepressant therapy (monoaminergic antidepressant). Sirukumab will be administered as a subcutaneous injection three times during the 12-week double blind treatment period.
Recruiting Patients: Yes